Spero Therapeutics (SPRO) Restructuring Costs (2022 - 2025)
Spero Therapeutics posted quarterly Restructuring Costs of $83000.0 for Q2 2025, down 52.57% on a QoQ basis from $175000.0 in Q1 2025.
Spero Therapeutics (SPRO) has 3 years of Restructuring Costs data on file, last reported at $83000.0 in Q2 2025.
- For the quarter ending Q2 2025, Restructuring Costs changed N/A year-over-year to $83000.0; the trailing twelve-month figure through Mar 2026 stood at $83000.0 (down 92.11% YoY), and the FY2025 full-year result was $258000.0, down 70.58% from the prior year.
- Restructuring Costs for Q2 2025 stood at $83000.0, down from $175000.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $11.8 million in Q2 2022 and bottomed at -$8.6 million in Q4 2022.
- The 3-year median for Restructuring Costs is $129000.0 (2025), against an average of $702166.7.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 83,000.00 |
| Mar 31, 2025 | 175,000.00 |
| Dec 31, 2024 | 877,000.00 |
| Dec 31, 2022 | -8.62 Mn |
| Sep 30, 2022 | -152,000.00 |
| Jun 30, 2022 | 11.85 Mn |